Juvenile toxicity assessment of d,l-methylphenidate in rats

David A Beckman1, Marilynn Schneider, Maureen Youreneff

  • 1Safety Profiling & Assessment, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA. david.beckman@novartis.com

Insights

Oral methylphenidate (MPH) in rats during development caused lasting behavioral changes. The no-observed-adverse-effect level was 5 mg/kg/day, with higher doses causing significant effects.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Toxicology

Background:

  • Oral methylphenidate (MPH) administration was studied during key postnatal development periods in rats.
  • The research aimed to identify potential chronic effects of MPH exposure.

Purpose of the Study:

  • To assess the chronic effects of oral methylphenidate (MPH) on developing rats.
  • To determine the no-toxicologic-effect-level (NTEL) for MPH in this model.

Main Methods:

  • Wistar Hannover rats were cross-fostered and administered MPH (5, 50, 100 mg/kg/day) from postnatal day 7 to 70.
  • Evaluations included clinical signs, body weight, behavior, pathology, toxicokinetics, and fertility.

Main Results:

  • MPH induced dose-dependent behavioral changes, including increased locomotor activity and cage biting, which resolved post-treatment.
  • Decreased body weight and altered motor activity in open field tests were observed at higher doses (≥50 mg/kg/day).
  • Some learning deficits were noted at 100 mg/kg/day, but were considered of nominal significance.

Conclusions:

  • Chronic oral MPH administration can lead to enduring behavioral effects in developing rats.
  • The no-toxicologic-effect-level was determined to be 5 mg/kg/day, with specific AUC values provided for males and females.
Abstract

Related Concept Videos

Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Drug Toxicity: Overview01:00

Drug Toxicity: Overview

Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...